Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.48 |
| ▸ | TACR1 | P25103 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | ATF1 | P18846 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3059654 | 0.88 | GAA (0.50) | PDK1TACR1GAATSHRATF1 | |
| SCHEMBL4661455 | 0.88 | GAA (0.50) | RAB9APDK1TACR1GAATSHR | |
| SCHEMBL3044246 | 0.86 | RAB9A (0.57) | RAB9APDK1GAATSHRNOS3 | |
| SCHEMBL3043556 | 0.85 | RAB9A (0.65) | RAB9APDK1GAATSHRNOS3 | |
| SCHEMBL3065409 | 0.85 | GAA (0.63) | RAB9APDK1GAATSHRKMT2A | |
| SCHEMBL3052473 | 0.84 | NOS3 (0.61) | RAB9APDK1GAATSHRNOS3 | |
| SCHEMBL3043503 | 0.82 | PDK1 (0.51) | RAB9APDK1NOS3NOS1NOS2 | |
| SCHEMBL3055205 | 0.82 | RAB9A (0.58) | RAB9APDK1GAATSHRNOS3 | |
| SCHEMBL3064672 | 0.82 | RAB9A (0.55) | RAB9APDK1GAATSHRNOS3 | |
| SCHEMBL3058609 | 0.81 | NOS1 (0.51) | TACR1HDAC6HDAC1HDAC8NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| CN-101405268-A | Amide derivatives and their use for the treatment of protein-related diseases | NOVARTIS AG (CH) | 2009-04-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | HRH4, CNR1, CNR2 | RAB9A 1263/4885PDK1 2335/4885TACR1 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.